Effects of a single dose of terlipressin on transcutaneous oxygen pressures

References

• Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;CD002147.
   PubMedGoogle Scholar
• Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81–95.
   PubMed Web of Science ®Google Scholar
• Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105–40.
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310–18.
   PubMed Web of Science ®Google Scholar
• Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51–9.
   PubMedGoogle Scholar
• Blei AT, Groszmann RJ, Gusberg R, Conn HO. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci 1980;25:688–94.
   PubMedGoogle Scholar
• Forsling ML, Aziz LA, Miller M, Davies R, Donovan B. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 1980;85:237–44.
   PubMed Web of Science ®Google Scholar
• Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994;203:72–9.
   PubMedGoogle Scholar
• Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385–94.
   PubMed Web of Science ®Google Scholar
• Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin (‘Glypressin’) versus vasopressin in the early treatment of oesophageal varices. Lancet 1982;2:66–8.
   PubMed Web of Science ®Google Scholar
• Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870–5.
   PubMed Web of Science ®Google Scholar
• Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, Arroyo V, Rodes J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35–41.
   PubMed Web of Science ®Google Scholar
• Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999;22:147–51.
   PubMedGoogle Scholar
• Ray SA, Buckenham TM, Belli AM, Taylor RS, Dormandy JA. The predictive value of laser Doppler fluxmetry and transcutaneous oximetry for clinical outcome in patients undergoing revascularisation for severe leg ischaemia. Eur J Vasc Endovasc Surg 1997;13:54–9.
   PubMedGoogle Scholar
• Ubbink DT, Jacobs MJ, Tangelder GJ, Slaaf DW, Reneman RS. The usefulness of capillary microscopy, transcutaneous oximetry and laser Doppler fluxmetry in the assessment of the severity of lower limb ischaemia. Int J Microcirc Clin Exp 1994;14:34–44.
   PubMedGoogle Scholar
• Misuri A, Lucertini G, Nanni A, Viacava A, Belardi P. Predictive value of transcutaneous oximetry for selection of the amputation level. J Cardiovasc Surg (Torino) 2000;41:83–7.
   PubMed Web of Science ®Google Scholar
• Poredos P, Rakovec S, Guzic-Salobir B. Determination of amputation level in ischaemic limbs using tcPO2 measurement. Vasa 2005;34:108–12.
   PubMedGoogle Scholar
• Ubbink DT, Kitslaar PJ, Tordoir JH, Reneman RS, Jacobs MJ. Skin microcirculation in diabetic and non-diabetic patients at different stages of lower limb ischaemia. Eur J Vasc Surg 1993;7:659–6.
   PubMedGoogle Scholar
• Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360–8.
   PubMed Web of Science ®Google Scholar
• Ertmer C, Rehberg S, Morelli A, Westphal M. Current place of vasopressin analogues in the treatment of septic shock. Curr Infect Dis Rep 2008;10:362–7.
   PubMedGoogle Scholar
• Scharte M, Meyer J, Van AH, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001;29:1756–60.
   PubMed Web of Science ®Google Scholar
• Morelli A, Ertmer C, Lange M, Dunser M, Rehberg S, Van AH, Pietropaoli P, Westphal M. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008;100:494–503.
   PubMed Web of Science ®Google Scholar
• Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439–47.
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105–10.
   PubMed Web of Science ®Google Scholar
• Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007;28:623-9.
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009;137:1179-81.
   PubMed Web of Science ®Google Scholar
• Angeli P, Fasolato S, Cavallin M, Maresio G, Callegaro A, Sticca A, Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: Results of a controlled clinical study. Hepatology 2008;48:LB3.
   Google Scholar
• Di MA, Bracci E, Cappa FM, Casadio R, Zambruni A, Fontana K, Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome. Dig Liver Dis 2008;40:304–5.
   PubMedGoogle Scholar
• Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol 2007;64:550–2.
   PubMedGoogle Scholar
• Lee JS, Lee HS, Jung SW, Han WS, Kim MJ, Lee SW, Choi JH, Kim CD, Ryu HS, Hyun JH. A case of peripheral ischemic complication after terlipressin therapy. Korean J Gastroenterol 2006;47:454–7.
   PubMedGoogle Scholar
• Megarbane H, Barete S, Khosrotehrani K, Izzedine H, Moguelet P, Chosidow O, Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin). Dermatology 2009;218:334–7.
   PubMedGoogle Scholar
• Vaccaro F, Giorgi A, Riggio O, De SA, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003;35:503–6.
   PubMedGoogle Scholar
• Oh JE, Ha JS, Cho DH, Yu GJ, Shim SG. A case of ischemic skin necrosis after glypressin therapy in liver cirrhosis. Korean J Gastroenterol 2008;51:381–4.
   PubMedGoogle Scholar
• Posada C, Feal C, Garcia-Cruz A, Alvarez V, Alvarez M, Cruces MJ. Cutaneous necrosis secondary to terlipressin therapy. Acta Derm Venereol 2009;89:434–5.
   PubMedGoogle Scholar